This narrative review (55 references, 7 pages) synthesizes epidemiology, histology, immunohistochemistry, site-specific subtypes, grading, staging, and genetics of luminal GI neuroendocrine tumors (NETs). Its central, well-supported conclusion: despite histologic homogeneity, behavior varies dramatically by site, and mitotic index/Ki-67 grading combined with size/stage remains the strongest behavior predictor.
Key quantitative content. The review reports a 5-fold SEER incidence rise (1.09 to 5.25 per 100,000, 1973β2004), attributing much of it to improved detection rather than confirmed true incidence increase . Grading thresholds (G1 <2%, G2 3β30%, G3 >20% Ki-67/mitotic index; counting β₯500, preferably 2000 cells in hotspots across 50 HPFs) are accurately summarized, and the authors candidly note the 3% G1/G2 cutoff lacks empirical clinical validation β a genuinely critical point rare in reviews of that era.
Critical assessment. Strengths: practical pathology guidance (Solcia-based ECL hyperplasia criteria with 5-cell/150 Β΅m/500 Β΅m thresholds; psammoma-body clue for duodenal somatostatinomas; CDX-2 vs TTF-1 lineage markers; MANEC vs neuroendocrine-marker-positive adenocarcinoma distinction), and honest acknowledgment that ENETS and AJCC/UICC staging diverge, notably for appendiceal T2/T3 criteria .
Blindspots and limitations. No systematic search strategy or PRISMA methodology; no meta-analytic synthesis; genetic coverage is thin (only Banck and Francis/CDKN1B studies cited). The esophagus section rests on 4-case and 3-case series β anecdotal by design. Incidence trends conflate detection effects with biology without quantification. No funding or COI statements appear in the available text, limiting transparency assessment. The WHO 2010 framework cited has since been superseded (2019 edition introduced G3 well-differentiated NET vs NEC distinctions), so grading claims have a limited knowledge half-life β a weakness inherent to a fast-moving field, which the authors themselves anticipated.
What would change the conclusions: validated large-cohort data redefining the G1/G2 boundary, or sequencing studies overturning the CDKN1B/p27 tumor-suppressor model for small-intestinal NETs would directly falsify core claims.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.